ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT03575078
Phase
PHASE1
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ARQ761, Olaparib — DRUG
    ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily

Study Details

Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of ARQ761 and a PARP inhibitor, Olaparib

Key Dates

First listed
Jul 2, 2018
Start date
Jun 25, 2018
Status verified
Sep 2019
Primary completion
May 15, 2019
Completion
May 15, 2019

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Maximum tolerated dose of ARQ761 in combination with Olaparib.
    ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily

Primary Outcome Measure

The maximum tolerated dose of ARQ761 in combination with Olaparib. [ Time Frame: Day 1-28 ]

Related Studies